NTUS / Natus Medical Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G 1 a2022-07x21form15.htm 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-33001 NATUS MEDICAL INCORPORATED (

Third Amended and Restated Bylaws of Natus Medical Incorporated, dated July 21, 2022

THIRD AMENDED AND RESTATED BYLAWS OF NATUS MEDICAL INCORPORATED ARTICLE I. OFFICES Section 1.Registered Office. The registered office of Natus Medical Incorporated, a Delaware corporation (the ?Corporation?), shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2.Other Offices. The Corporation may also have offices at such other places both within and without the St

As filed with the Securities and Exchange Commission on July 21, 2022

As filed with the Securities and Exchange Commission on July 21, 2022 Registration Nos.

As filed with the Securities and Exchange Commission on July 21, 2022

As filed with the Securities and Exchange Commission on July 21, 2022 Registration Nos.

Second Amended and Restated Certificate of Incorporation of Natus Medical Incorporated, dated July 21, 2022

SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NATUS MEDICAL INCORPORATED FIRST: The name of the corporation (hereinafter sometimes referred to as the ?Corporation?) is: Natus Medical Incorporated SECOND: The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 NATUS MEDICAL I

S-8 POS 1 a2022-07x21formsx8.htm S-8 POS As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NATUS MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Delaware 77-0154833 (State or other

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 NATUS MEDICAL I

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, WI (July 21, 2022) - Natus Medical Incorporated (NASDAQ: NTUS) (the ?Company? or ?Natus?), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II

As filed with the Securities and Exchange Commission on July 21, 2022

POS AM 1 a2022-07x21formsx3.htm POS AM As filed with the Securities and Exchange Commission on July 21, 2022 Registration Nos. 333-171489 333-150503 333-133480 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration Statement No. 333-171489 Form S-3 Registration Statement No. 333-150503 Form S-3 Registration Statement No. 333

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 NATUS MEDICAL I

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 NATUS MEDICAL I

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 NATUS MEDICAL I

S-8 POS 1 a2022-07x21formsx8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 21, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NATUS MEDICAL INCORPORATED (Exact name of registrant as specified in its charter) Delaware 77-0154833 (State or oth

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 21, 2022 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2022 (July 6, 2022) Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware (State or other jurisdiction

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 15, 2022 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant?? Filed by a Party other than the Registrant??? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) Delaware 000-33001 (State or other jurisdiction of incorporation) (Commission file numbe

SD 1 a2021formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) Delaware 000-33001 (State or other jurisdiction of incorporation) (Commission file number) 3150 Pleasant View Road, Middleton, WI 53562 (Address of principal executive offices) (Zip code) Drew Davies, 608-829-8500

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Natus Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Natus Medical Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee rate Amount of Filing Fee Fees to be Paid $ 1,196,399,507.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PREM14A 1 ny20004245x1prem14a.htm PREM14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Part-time Employment Agreement, dated as April 2, 2022, by and between the Company and Dong-Chune Christopher Chung

PART-TIME EMPLOYMENT AGREEMENT This Agreement is made by Natus Medical Incorporated (?Natus?) and Dong-Chune Christopher Chung (?Employee?), effective as of April 2, 2022 (the ?Effective Date?) for the purpose of setting forth the terms and conditions by which Natus will acquire Employee?s services on a part-time basis.

Natus Medical Announces First Quarter 2022 Financial Results Q1-2022 Key Results Revenue (millions) $119.8 Ø Total revenue increased 4.2% compared to Q1 2021 Ø Generated $8.9 million in operating cash flow GAAP EPS $0.06 Non-GAAP EPS $0.22

Natus Medical Announces First Quarter 2022 Financial Results Q1-2022 Key Results Revenue (millions) $119.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2022 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confiden

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

DEFA14A 1 ny20002509x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash

Exhibit 99.1 Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: ? Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value ? Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, WI (April 18, 2022) ? Natus Medical Incorporated (NASDAQ: NTUS), (the ?Company? or ?Natu

Retention Agreement, dated as of April 17, 2022, by and among Natus Medical Incorporated, Prince Parent Inc. and Thomas J. Sullivan.

Exhibit 10.1 Natus Medical Incorporated 12301 Lake Underhill Rd. Suite 201 Orlando, FL 32828 April 17, 2022 Thomas J. Sullivan Address on File Retention Agreement Dear Tom: As you are aware, Natus Medical Incorporated, a Delaware Corporation (the ?Company?), has entered into an Agreement and Plan of Merger, made and entered into as of the date hereof (the ?Merger Agreement?), by and among the Comp

Retention Agreement, dated as of April 17, 2022, by and among Natus Medical Incorporated, Prince Parent Inc. and Thomas J. Sullivan.

Exhibit 10.1 Natus Medical Incorporated 12301 Lake Underhill Rd. Suite 201 Orlando, FL 32828 April 17, 2022 Thomas J. Sullivan Address on File Retention Agreement Dear Tom: As you are aware, Natus Medical Incorporated, a Delaware Corporation (the ?Company?), has entered into an Agreement and Plan of Merger, made and entered into as of the date hereof (the ?Merger Agreement?), by and among the Comp

Agreement and Plan of Merger, dated as of April 17, 2022, by and among Natus Medical Incorporated, Prince Parent Inc. and Prince Mergerco Inc.*

EXHIBIT 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among PRINCE PARENT INC., PRINCE MERGERCO INC. AND NATUS MEDICAL INCORPORATED Dated as of April 17, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 17 1.3 Certain Interpretations 19 Article II THE MERGER 21 2.1 The Merger 21 2.2 The Effective Time 21 2.3 The

Press Release of Natus Medical Incorporated, dated as of April 18, 2022.

Exhibit 99.1 Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: ? Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value ? Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, WI (April 18, 2022) ? Natus Medical Incorporated (NASDAQ: NTUS), (the ?Company? or ?Natu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2022 (April 17, 2022) Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware (State or other jurisdict

Agreement and Plan of Merger, dated as of April 17, 2022, by and among Natus Medical Incorporated, Prince Parent Inc. and Prince Mergerco Inc.*

EXHIBIT 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among PRINCE PARENT INC., PRINCE MERGERCO INC. AND NATUS MEDICAL INCORPORATED Dated as of April 17, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Additional Definitions 17 1.3 Certain Interpretations 19 Article II THE MERGER 21 2.1 The Merger 21 2.2 The Effective Time 21 2.3 The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2022 (April 17, 2022) N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 18, 2022 (April 17, 2022) Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware (State or other jurisdict

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SE

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS M

Significant Subsidiaries of the Registrant

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT STATE or JURISDICTION of INCORPORATION PERCENT of OWNERSHIP Natus Manufacturing Limited Ireland 100 % Natus Medical Denmark ApS Denmark 100 % Excel-Tech Corp. Canada 100 %

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2022 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Medical Announces Fourth Quarter 2021 Financial Results

Natus Medical Announces Fourth Quarter 2021 Financial Results Q4-2021 Key Results Revenue (millions) $128.

NTUS / Natus Medical Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01492-natusmedicalinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Natus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 639050103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate

NTUS / Natus Medical Inc / VICTORY CAPITAL MANAGEMENT INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 1)* Natus Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

NTUS / Natus Medical Inc / Allspring Global Investments Holdings, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NATUS MEDICAL (Name of Issuer) COM (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [

Natus Announces Preliminary 2021 Fourth Quarter and Full Year Revenue

Natus Announces Preliminary 2021 Fourth Quarter and Full Year Revenue PLEASANTON, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2022 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 13, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Medical Announces Executive Transition Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance

Natus Medical Announces Executive Transition Thomas J. Sullivan Appointed President & Chief Executive Officer No Change To 4th Quarter Guidance PLEASANTON, Calif. (December 17, 2021) - Natus Medical Incorporated (NASDAQ:NTUS) (the ?Company? or ?Natus?), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients

Employment Agreement, dated as of December 13, 2021, by and between the Company and Thomas J. Sullivan

NATUS MEDICAL INCORPORATED THOMAS J. SULLIVAN EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is entered into as of December 13, 2021 by and between Natus Medical Incorporated (?Natus? or the ?Company?), and Thomas J. Sullivan (?Executive?). This Agreement shall become effective on the day Executive actually commences employment with the Company (the ?Effective Date?), which in no

Separation Agreement, dated as of December 13, 2021, by and between the Company and Jonathan A. Kennedy

December 13, 2021 Via e-mail Jonathan A. Kennedy Dear Mr. Kennedy: As we have discussed, your employment with Natus Medical Incorporated (the ?Company?) has terminated, effective as of December 13, 2021 (the ?Separation Date?). The purpose of this letter (this ?Agreement?) is to confirm the terms concerning your separation from employment, as follows: 1.Resignation; Final Salary and Vacation Pay.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 N

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Medical Announces Third Quarter 2021 Financial Results Q3-2021 Key Results Revenue (millions) $113.9 Ø Revenue increased 11% compared to Q3 2020 Ø Generated $7.1 million in operating cash flow GAAP EPS $0.16 Non-GAAP EPS $0.28

Natus Medical Announces Third Quarter 2021 Financial Results Q3-2021 Key Results Revenue (millions) $113.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction o

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors PLEASANTON, Calif. (August 18, 2021) - Natus Medical Incorporated (NASDAQ:NTUS) (the ?Company? or ?Natus?), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Natus Medical Announces Second Quarter 2021 Financial Results Q2-2021 Key Results Revenue (millions) $116.0 Ø Revenue increased 37% compared to Q2 2020 Ø Generated $19.4 million in operating cash flow Ø GAAP and Non-GAAP EPS increased by $0.36 and $0

Natus Medical Announces Second Quarter 2021 Financial Results Q2-2021 Key Results Revenue (millions) $116.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 5, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Medical Incorporated 2021 Equity Incentive Plan

Exhibit 4.1 NATUS MEDICAL INCORPORATED 2021 EQUITY INCENTIVE PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in the future, by offering them an opportunity to participate in the Company?s future

As filed with the Securities and Exchange Commission on July 16, 2021

As filed with the Securities and Exchange Commission on July 16, 2021 Registration No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson

Natus Chairperson Dr. Barbara Paul Retires; Board Elects Current Board Member Joshua Levine as Chairperson PLEASANTON, Calif. (June 28, 2021) - Natus Medical Incorporated (NASDAQ:NTUS) (the ?Company? or ?Natus?), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced Dr. Barbara

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of Incorporati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of Incorporation) (I.R.S. Employer Identification No.) 6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566 (Address of principal executive offices)

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Natus Medical Announces First Quarter 2021 Financial Results Q1-2021 Key Results Revenue (millions) $114.9 Ø Revenue increased 5% compared to Q1 2020 and in-line with Q1 2019 Ø Generated $24.7 million in operating cash flow Ø GAAP and Non-GAAP EPS in

Natus Medical Announces First Quarter 2021 Financial Results Q1-2021 Key Results Revenue (millions) $114.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 6, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of In

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confiden

- DEFA14A

DEFA14A 1 nc10023368x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS M

Significant Subsidiaries of the Registrant

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT STATE or JURISDICTION of INCORPORATION PERCENT of OWNERSHIP Natus Medical Incorporated Delaware Natus Manufacturing Limited Ireland 100 % Natus Medical Denmark ApS Denmark 100 % Excel-Tech Corp. Canada 100 %

Natus Medical Announces Fourth Quarter 2020 Financial Results

Natus Medical Announces Fourth Quarter 2020 Financial Results Q4-2020 Key Results Revenue (millions) $118.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Natus Medical Inc. Title of Class of Securities: Common Stock CUSIP Number: 639050103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Natus Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) December

SC 13G 1 natusmedical13g123120.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Natus Medical Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate t

1

EX-99.1 2 a2021-01x08q420guidanceand.htm EX-99.1 Natus Updates Fourth Quarter 2020 Revenue Guidance and Announces Investor Conference Attendance •39th Annual JP Morgan Healthcare Conference •23rd Annual Needham Growth Conference PLEASANTON, Calif. (January 8, 2021) - Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the d

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2021 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction o

Amendment to Credit Agreement, dated August 10, 2020, between the Company, JP Morgan Chase Bank, N.A. and Citibank, N.A.

EX-10.1 2 exhibit-amendmentno1to.htm EX-10.1 EXECUTION COPY AMENDMENT NO. 1 Dated as of August 10, 2020 to CREDIT AGREEMENT Dated as of September 23, 2016 THIS AMENDMENT NO. 1 (this “Amendment”) is made as of August 10, 2020 by and among NATUS MEDICAL INCORPORATED, a Delaware corporation (the “Borrower”), the financial institutions listed on the signature pages hereof and JPMORGAN CHASE BANK, N.A.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 N

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 29, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Medical Announces Third Quarter 2020 Financial Results

Natus Medical Announces Third Quarter 2020 Financial Results Q3-2020 Key Results Revenue (millions) $102.

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction o

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Natus Medical Announces Second Quarter 2020 Financial Results

EX-99.1 2 a2020-q2earningsrelease.htm EX-99.1 Natus Medical Announces Second Quarter 2020 Financial Results Q2-2020 Key Results Revenue (millions) $84.8 Ø Newborn Care revenue increased 1% compared to second quarter last year Ø Reduced debt by $13.0 million during the quarter Ø NICVIEW II released during the quarter GAAP loss per share $0.26 Non-GAAP loss per share $0.13 PLEASANTON, Calif. (July 3

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 18, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

- SD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of Incorporation) (I.R.S. Employer Identification No.) 6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566 (Address of principal executive offices)

Conflict Minerals Report for the calendar year ended December 31, 2019.

Exhibit 1.01 Natus Medical Incorporated Conflict Minerals Report For The Year Ended December 31, 2019 Natus Medical Incorporated (herein referred to as “Natus Medical”, the “Company”, “we”, “us”, or “our”) has included this Conflict Minerals Report as an exhibit to its Form SD as contemplated by Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Confl

- DEFA14A

DEFA14A 1 nc10009615x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only

- DEF 14A

DEF 14A 1 nc10009615x1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 4, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of In

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Medical Announces First Quarter 2020 Financial Results

Natus Medical Announces First Quarter 2020 Financial Results Q1-2020 Key Results Revenue (millions) $109.

1

Natus Announces Preliminary First Quarter Revenue PLEASANTON, Calif. (April 6, 2020) - Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced its first quarter revenue estimate and withdrew its full year 2020 g

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 6, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 18, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

1

Natus Medical Announces the Appointment of Ilan Daskal to the Board of Directors PLEASANTON, Calif.

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS M

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 6, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdictio

Description of Common Stock

Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF COMMON STOCK The following description of the common stock, par value $0.001 per share of Natus Medical Incorporated (“Natus,” we,” “us,” and “our”) is based upon our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporati

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Revenue $

Update to Natus Medical Fourth Quarter and Full Year 2019 Financial Results • Fourth quarter GAAP earnings per diluted share changed to $0.

Significant Subsidiaries of the Registrant

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT STATE or JURISDICTION of INCORPORATION PERCENT of OWNERSHIP Natus Medical Incorporated Delaware Natus Manufacturing Ireland, Ltd. Ireland 100 % Natus Medical Denmark ApS Denmark 100 % Excel Tech Corp. (Xltek) Canada 100 %

BABY / Natus Medical, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Natus Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 639050103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 6, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year Ended December 31, 2019 December 31, 2018 December 31, 2019 December 31, 2018 Revenue $

Natus Medical Announces Fourth Quarter and Full Year 2019 Financial Results • Fourth quarter revenue of $131.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2020 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Reaffirms Fourth Quarter 2019 Guidance and will Present at the 38th Annual JP Morgan Healthcare Conference

Natus Reaffirms Fourth Quarter 2019 Guidance and will Present at the 38th Annual JP Morgan Healthcare Conference Pleasanton, Calif.

Natus Announces $50 Million Share Repurchase Program

Natus Announces $50 Million Share Repurchase Program Pleasanton, Calif., December 17, 2019 - Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that its Board of Directors has approved a stock repurchase p

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 17, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 12, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Second Amended and Restated Bylaws of Natus Medical Incorporated

SECOND AMENDED AND RESTATED BYLAWS OF NATUS MEDICAL INCORPORATED (As in effect on December 12, 2019) Article 1 Offices Section 1.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 N

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, 2019 September 30, 2018 September 30, 2019 September 30

Natus Medical Announces Third Quarter 2019 Financial Results • Third quarter revenue of $123.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 24, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Six Months Ended June 30, 2019 June 30, 2018 June 30, 2019 June 30, 2018 Revenue $ 125,

Natus Medical Announces Second Quarter 2019 Financial Results • Second quarter revenue of $125.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2019-q2earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-015483

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Medical Announces NASDAQ Ticker Symbol Change to “NTUS”

EX-99.1 2 a2019-07x25tickersymbolcha.htm EXHIBIT 99.1 Natus Medical Announces NASDAQ Ticker Symbol Change to “NTUS” PLEASANTON, Calif. (July 25, 2019) - Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced th

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of I

Certificate of Amendment of the Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State as of June 5, 2019

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NATUS MEDICAL INCORPORATED Natus Medical Incorporated, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY THE FOLLOWING: FIRST: That the name of the Corporation is Natus Medical Incorporated. SECOND:

Conflict Minerals Report for the calendar year ended December 31, 2018.

Exhibit 1.01 Natus Medical Incorporated Conflict Minerals Report For The Year Ended December 31, 2018 Natus Medical Incorporated (herein referred to as “Natus Medical”, the “Company”, “we”, “us”, or “our”) has included this Conflict Minerals Report as an exhibit to its Form SD as contemplated by Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Confl

BABY / Natus Medical, Inc. SD - - SD

SD 1 a2018formsd.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of Incorporation) (I.R.S. Employer Identification No.) 6701 Koll Center Parkway, Suite 120, Pleasanton, CA 94566 (Address of princ

Quarterly Report - 10-Q

10-Q 1 baby3311910-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio

Amended and Restated Bylaws of Natus Medical Incorporated, as amended April 9, 2019

EX-3.4 2 exhibit34amendedandrestate.htm EXHIBIT 3.4 AMENDED AND RESTATED BYLAWS OF NATUS MEDICAL INCORPORATED (As in effect on December 7, 2018, as amended on April 9, 2019) Article 1 Offices Section 1.1. Registered Office. The registered office of the Corporation which is required by the state of Delaware to be maintained in the state of Delaware shall be the registered office named in the charte

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 25, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended March 31, 2019 March 31, 2018 Revenue $ 114,757 $ 128,609 Cost of revenue 46,370 55,369 Inta

Update to Natus Medical First Quarter 2019 Financial Results • GAAP loss per share changed to $0.

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended March 31, 2019 March 31, 2018 Revenue $ 114,757 $ 128,609 Cost of revenue 46,370 55,369 Inta

EX-99.1 2 a2019-q1earningsrelease.htm EXHIBIT 99.1 Natus Medical Announces First Quarter 2019 Financial Results • First quarter revenue of $114.8 million • First quarter GAAP loss per share of $0.74; non-GAAP earnings per share of $0.09 PLEASANTON, Calif. (April 25, 2019) - Natus Medical Incorporated (NASDAQ: BABY) (the “Company” or “Natus”), a leading provider of medical devices and services, tod

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2019-q1earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-01548

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 formdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm

BABY / Natus Medical, Inc. DEF 14A

DEF 14A 1 formdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 9, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Amendment to the Amended and Restated Bylaws of Natus Medical Incorporated

EX-3.1 2 exhibit31-textofamendmentt.htm EXHIBIT 3.1 Exhibit 3.1 Text of Amendment to Section 2.4 of the Amended and Restated Bylaws of Natus Medical Incorporated Section 2.4 of Natus Medical Incorporated's amended and restated bylaws shall be amended to delete the text “by the holders of at least 30% of the shares of the Corporation’s capital stock entitled to vote at such meeting” and replace suc

BABY / Natus Medical, Inc. PRE 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 1, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Announces Sale of Medix Business “Local Management to acquire the stock of Natus' Argentinian subsidiary”

EX-99.1 2 a2019-04x02saleofmedixbusi.htm EXHIBIT 99.1 Natus Announces Sale of Medix Business “Local Management to acquire the stock of Natus' Argentinian subsidiary” PLEASANTON, Calif. (April 2, 2019) - Natus Medical Incorporated (NASDAQ:BABY) (the “Company” or “Natus”), a leading provider of medical devices and services, today announced that it has signed a definitive agreement to sell its wholly

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K/A 1 a2019-03x158xkacommitteeas.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 11, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commiss

BABY / Natus Medical, Inc. 10-K (Annual Report)

10-K 1 baby12311810-k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2018 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commissi

Significant Subsidiaries of the Registrant

EX-21.1 2 exhibit211123118.htm EXHIBIT 21.1 EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT STATE or JURISDICTION of INCORPORATION PERCENT of OWNERSHIP Natus Medical Incorporated Delaware Natus Manufacturing Ireland, Ltd. Ireland 100 % Natus Medical Denmark ApS Denmark 100 % Excel Tech Corp. (Xltek) Canada 100 %

BABY / Natus Medical, Inc. / SILVERCREST ASSET MANAGEMENT GROUP LLC - SC 13G/A Passive Investment

SC 13G/A 1 d689204dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Natus Medical Incorporated (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement)

JOINT FILING AGREEMENT

EX-1 2 d689204dex1.htm EX-1 Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2019, is by and among Silvercrest Asset Management Group LLC, Silvercrest L.P. and Silvercrest Asset Management Group Inc. (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year Ended December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Revenue $

Natus Medical Announces Fourth Quarter and Full Year 2018 Financial Results • Reports record fourth quarter revenue of $141.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2018-q4earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 31, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-01

Natus Medical Announces Continued Board Refreshment with Two New Independent Directors

Natus Medical Announces Continued Board Refreshment with Two New Independent Directors PLEASANTON, Calif.

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 11, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

BABY / Natus Medical, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* NATUS MEDICAL INC (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

BABY / Natus Medical, Inc. / VANGUARD GROUP INC Passive Investment

natusmedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Natus Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 639050103 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to

BABY / Natus Medical, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 dfs699.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NATUS MEDICAL INC (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

BABY / Natus Medical, Inc. S-8

As filed with the Securities and Exchange Commission on January 22, 2019 Registration No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 15, 2019 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Natus Announces Organizational Enhancements, Key Leadership Appointments "One Natus" Plan to Focus on More Effectively Meeting Customers' Evolving Needs, and Creating a More Efficient Operating Model Expects to Exit Non-Core Businesses

EX-99.1 2 a2019-01x15pressrelease.htm EXHIBIT 99.1 Natus Announces Organizational Enhancements, Key Leadership Appointments "One Natus" Plan to Focus on More Effectively Meeting Customers' Evolving Needs, and Creating a More Efficient Operating Model Expects to Exit Non-Core Businesses PLEASANTON, Calif., Jan. 15, 2019 - Natus Medical Incorporated (NASDAQ:BABY) (the “Company” or “Natus”) today ann

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 13, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

Form of Stock Option Awards Agreement under the 2018 Equity Incentive Plan

EX-10.1.1 3 ex1011-2018eipstockoptiona.htm EXHIBIT 10.1.1 NATUS MEDICAL INCORPORATED 2018 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Natus Medical Incorporated (the “Company”) 2018 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Stock Option Grant and the electronic representation of this Notice of S

2018 Equity Incentive Plan

EX-10.1 2 ex101-2018equityincentivep.htm EXHIBIT 10.1 NATUS MEDICAL INCORPORATED 2018 EQUITY INCENTIVE PLAN (amended and restated October 29, 2018) 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that exist now or in t

Form of Performance Stock Unit Agreement under the 2018 Equity Incentive Plan

EX-10.1.4 6 ex1014-2018eippsuagreement.htm EXHIBIT 10.1.4 NATUS MEDICAL INCORPORATED 2018 EQUITY INCENTIVE PLAN NOTICE OF PERFORMANCE RESTRICTED STOCK UNIT AWARD Unless otherwise defined herein, the terms defined in the Natus Medical Incorporated (the “Company”) 2018 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Performance Restricted Stock Unit Award and the ele

Form of Restricted Stock Award Agreement under the 2018 Equity Incentive Plan

NATUS MEDICAL INCORPORATED 2018 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Natus Medical Incorporated 2018 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Award and any electronic representation of this Notice of Restricted Stock Award established and maintained by Natus Medical Incorporated (“Natus” or the “Company”) or a third party designated by the Company (this “Notice”).

Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan

NATUS MEDICAL INCORPORATED 2018 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD Unless otherwise defined herein, the terms defined in the Natus Medical Incorporated (the “Company”) 2018 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Award established and maintained by the Company or a third party designated by the Company (this “Notice”).

Amended and Restated Bylaws of Natus Medical Incorporated

EX-3.1 2 a2018-12x07bylawsnew.htm EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF NATUS MEDICAL INCORPORATED (As amended December 7, 2018) Article 1 Offices Section 1.1. Registered Office. The registered office of the Corporation which is required by the state of Delaware to be maintained in the state of Delaware shall be the registered office named in the charter documents of the Corporation, or such

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 7, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction

BABY / Natus Medical, Inc. DEFR14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the Commission Only (as permitted by Rule 1

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-11x09defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. 10-Q (Quarterly Report)

10-Q 1 baby9301810-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi

Form of Employment Agreement between Natus Medical Incorporated and Drew Davies dated October 1, 2018

EX-10.18 2 daviesdrew-employmentagree.htm EXHIBIT 10.18 Exhibit 10.18 NATUS MEDICAL INCORPORATED DREW DAVIES EMPLOYMENT AGREEMENT This Agreement is entered into as of October 1, 2018 (“Effective Date”), by and between Natus Medical Incorporated (“Company”), and Drew Davies (“Executive”). 1. Duties and Scone of Employment. (a)Positions and Duties. As of the Effective Date, Executive will serve as C

BABY / Natus Medical, Inc. DEFC14A

DEFC14A 1 a2018-11x02defc14adefiniti.htm DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the Commissi

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, 2018 September 30, 2017 September 30, 2018 September 30

Natus Medical Announces Third Quarter Financial Results • Reports record third quarter revenue of $130.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2018-q3earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 30, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0

Regulation FD Disclosure

8-K 1 a2018-09x178xkappointmento.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 17, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delawa

Natus Appoints Drew Davies Executive Vice-President and CFO

Natus Appoints Drew Davies Executive Vice-President and CFO PLEASANTON, Calif., September 17, 2018 - Natus Medical Incorporated (NASDAQ:BABY) today announced the appointment of Drew Davies as Executive Vice-President and Chief Financial Officer, effective October 1, 2018. Mr. Davies brings nearly 30 years of financial and operational expertise to Natus. Sharon Villaverde, who has served as Interim

Financial Statements and Exhibits

8-K 1 a2018-08x248xkkennedyemplo.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 24, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware

NATUS MEDICAL INCORPORATED JONATHAN A KENNEDY EMPLOYMENT AGREEMENT

Exhibit 99.1 NATUS MEDICAL INCORPORATED JONATHAN A KENNEDY EMPLOYMENT AGREEMENT This Employment Agreement (the “Employment Agreement”) is entered into as of August 24, 2018, (“Effective Date”) by and between Natus Medical Incorporated (“Natus” or the “Company”), and Jonathan A. Kennedy (“Executive”). The parties acknowledge and agree that upon execution of this Employment Agreement, that certain E

Terms of Resignation between Natus Medical Incorporated and James B. Hawkins dated July 11, 2018

exhibit1016 Exhibit 10.16 July 11, 2018 James B. Hawkins 1678 Orvieto Court Pleasanton, CA 94566 VIA HAND DELIVERY Re: Terms of Resignation Dear Jim: This letter confirms the agreement (“Agreement”) between you and Natus Medical Incorporated (the “Company”) concerning the terms of your resignation. 1. Resignation Date: July 11, 2018 is your last day of employment with the Company (the “Resignation

BABY / Natus Medical, Inc. 10-Q (Quarterly Report)

10-Q 1 baby6301810-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year Ended June 30, 2018 June 30, 2017 June 30, 2018 June 30, 2017 Revenue $ 130,653 $ 122,2

Natus Medical Announces Second Quarter Financial Results • Reports record second quarter revenue of $130.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2018-q2earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-015483

BABY / Natus Medical, Inc. 10-K/A (Annual Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission file numbe

BABY / Natus Medical, Inc. CORRESP

July 20, 2018 VIA EDGAR Kevin J. Kuhar Accounting Branch Chief Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Natus Medical Incorporated Form 10-K for the year ended December 31, 2017 Filed March 1, 2018 File No. 000-3300 Dear Mr. Kuhar: Thank you for your letter dated July 12, 2018 and your comment regarding our Form 10-K

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 11, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

Natus Medical Announces Leadership Changes Jim Hawkins Retires after 14 years as President and CEO Jonathan Kennedy Appointed President and Chief Executive Officer Board Appoints Barbara Paul, M.D. Chairperson Releases Preliminary Q2 2018 Revenue and

EX-99.1 2 a2018-07x11pressrelease.htm EXHIBIT 99.1 Natus Medical Announces Leadership Changes Jim Hawkins Retires after 14 years as President and CEO Jonathan Kennedy Appointed President and Chief Executive Officer Board Appoints Barbara Paul, M.D. Chairperson Releases Preliminary Q2 2018 Revenue and Conference Call Date PLEASANTON, Calif., July 11, 2018 - Natus Medical Incorporated (NASDAQ:BABY)

Current Report

8-K 1 a2018-06x268xksubmissionof.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 26, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77

BABY / Natus Medical, Inc. NATUS MEDICAL INCORPORATED

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Natus Medical Incorporated (Name of Registrant as Specified in Its Charter) Voce Catalyst Partners LP Voce Capital Management LLC Voce Capital LLC J.

BABY / Natus Medical, Inc. NATUS MEDICAL INC

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Natus Medical Incorporated (Name of Registrant as Specified in Its Charter) Voce Catalyst Partners LP Voce Capital Management LLC Voce Capital LLC J.

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-06x14defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. NATUS MEDICAL INC

DFAN14A 1 p18-1322dfan14a.htm NATUS MEDICAL INC SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additi

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-06x13defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. NATUS MEDICAL INC

DFAN14A 1 p18-1317dfan14a.htm NATUS MEDICAL INC SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additi

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-06x11defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the Commission Only (as permitted by Ru

BABY / Natus Medical, Inc. NATUS MEDICAL INC.

DFAN14A 1 p18-1280dfan14a.htm NATUS MEDICAL INC. SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Addit

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-06x04defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-06x04defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-05x31defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. DFAN14A

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 Natus Medical Incorporated (Name of Registrant as Specified in Its Charter) Voce Catalyst Partners LP Voce Capital Management LLC Voce Capital LLC J.

BABY / Natus Medical, Inc. PDF TO EXHIBIT 1

begin 644 p18-1246exhibit1.pdf M)5!$1BTQ+C4-)>+CS],-"C4R." P(&]B:@T\/"],:6YE87)I>F5D(#$O3" Q M,3(S-3%LU,C@@ M,C9=+TEN9F\@-3(W(# @4B],96YG=&@@-S8O4')E=B Q,3(R-#$W+U)O;W0@ M-3(Y(# @4B]3:7IE(#4U-"]4>7!E+UA2968O5ULQ(#(@,5T^/G-TO.VI'^MW&^G?>\SN\S.>;YP# '( F15P /P1Z"#ZT0&! MOCBH? #J=3)PI&TE,3ZI14;V4OI^V!Z'6$S UXTY0-]XF)TW^86RAGDRH M4!3))D8/?WQ%[C-!K?[@PH8#PQ- MJ\,:2M'I<[<[00%:WQWR*BP/F(?5 MES4OE:D* E)+-

Executing on a Proven Strategy To Deliver Shareholder Value May 2018 Forward‐Looking Statements This presentation contains forward‐looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regardin

babyinvestordeck Executing on a Proven Strategy To Deliver Shareholder Value May 2018 Forward‐Looking Statements This presentation contains forward‐looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus and including statements regarding projected second quarter and full year 2018 operating results, organic growth rates, expected future gross and operating margins, and the market opportunity for our products.

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 a2018-05x30defa14aschedule.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, f

BABY / Natus Medical, Inc. NATUS MEDICAL INC

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Natus Medical Incorporated (Name of Registrant as Specified in Its Charter) Voce Catalyst Partners LP Voce Capital Management LLC Voce Capital LLC J.

BABY / Natus Medical, Inc. NATUS MEDICAL INC

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 Natus Medical Incorporated (Name of Registrant as Specified In Its Charter) Voce Catalyst Partners LP Voce Capital LLC Voce Capital Management LLC J.

BABY / Natus Medical, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the Commission Only (as permitted by Ru

BABY / Natus Medical, Inc. DEFC14A

DEFC14A 1 a2018-05x18defc14adefiniti.htm DEFC14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the Commissi

BABY / Natus Medical, Inc. PRER14A

PRER14A 1 a2018-05x16prer14aprelimin.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 3) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary proxy statement o Confidential, for u

BABY / Natus Medical, Inc. CORRESP

DANIEL J. WINNIKE May 17, 2018 Email [email protected] Direct Dial (650) 335-7657 Via EDGAR AND OVERNIGHT DELIVERY Office of Mergers and Acquisitions U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tiffany Piland Posil, Special Counsel Bryan Hough, Staff Attorney Re: Natus Medical Incorporated Revised Preliminary Proxy Sta

BABY / Natus Medical, Inc. NATUS MEDICAL INC

PRRN14A 1 p18-1175prrn14a.htm NATUS MEDICAL INC SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐

BABY / Natus Medical, Inc. PRER14A

PRER14A 1 a2018-05x10prer14aprelimin.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary proxy statement o Confidential, for u

BABY / Natus Medical, Inc. CORRESP

DANIEL J. WINNIKE May 11, 2018 Email [email protected] Direct Dial (650) 335-7657 Via EDGAR AND OVERNIGHT DELIVERY Office of Mergers and Acquisitions U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Tiffany Piland Posil, Special Counsel Bryan Hough, Staff Attorney Re: Natus Medical Incorporated Revised Preliminary Proxy Sta

BABY / Natus Medical, Inc. 10-Q (Quarterly Report)

10-Q 1 baby3311810-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio

BABY / Natus Medical, Inc. NATUS MEDICAL INC.

PREC14A 1 p18-1093prec14a.htm NATUS MEDICAL INC. SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Addit

BABY / Natus Medical, Inc. PRER14A

PRER14A 1 a2018prer14apreliminarypro.htm PRER14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary proxy statement o Confidential, for u

BABY / Natus Medical, Inc. PREC14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary proxy statement o Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi

BABY / Natus Medical, Inc. 10-K/A (Annual Report)

10-K/A 1 baby12311710-ka2.htm 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.2 ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition pe

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended March 31, 2018 March 31, 2017 Revenue $ 128,609 $ 124,660 Cost of revenue 55,369 56,913 Inta

Natus Medical Announces First Quarter Financial Results • Reports record first quarter revenue of $128.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisdiction of

BABY / Natus Medical, Inc. DEFA14A

DEFA14A 1 schedule14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement o Confidential, for use of the C

BABY / Natus Medical, Inc. VOCE CATALYST PARTNERS LP

DFAN14A 1 p18-1030dfan14a.htm VOCE CATALYST PARTNERS LP SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitiv

BABY / Natus Medical, Inc. 10-K/A (Annual Report)

10-K/A 1 baby12311710-ka.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017 OR ¬ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Com

BABY / Natus Medical, Inc. 10-K (Annual Report)

10-K 1 baby12311710-k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commissi

Significant Subsidiaries of the Registrant

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT STATE or JURISDICTION of INCORPORATION PERCENT of OWNERSHIP Natus Medical Incorporated Delaware Natus Manufacturing Ireland, Ltd. Ireland 100 % Natus Europe Gmbh Germany 100 % Excel Tech Corp. (Xltek) Canada 100 % Medix I.C.S.A. Argentina 100 % Embla Systems, Ltd. Canada 100 %

Natus Announces $30 Million Share Repurchase Program

Exhibit Natus Announces $30 Million Share Repurchase Program Pleasanton, Calif., February 22, 2018 - Natus Medical Incorporated (NASDAQ: BABY) announced that its Board of Directors has authorized the repurchase of up to $30 million of the Company's common stock. The expiration date is set for February 26, 2019. The Company intends to use cash on hand, cash generated from operations, existing credi

Financial Statements and Exhibits, Other Events

8-K 1 a20188-ksharerepurchasepro.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delawar

JOINT FILING AGREEMENT

EX-1 Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2018, is by and among Silvercrest Asset Management Group LLC, Silvercrest L.

BABY / Natus Medical, Inc. / SILVERCREST ASSET MANAGEMENT GROUP LLC - SC 13G Passive Investment

SC 13G 1 d408771dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Natus Medical Incorporated (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check

BABY / Natus Medical, Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G Passive Investment

SC 13G 1 dfs679.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NATUS MEDICAL INC (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

BABY / Natus Medical, Inc. / VANGUARD GROUP INC Passive Investment

natusmedicalinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Natus Medical Inc Title of Class of Securities: Common Stock CUSIP Number: 639050103 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to

BABY / Natus Medical, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NATUS MEDICAL INC (Name of Issuer) Common Stock (Title of Class of Securities) 639050103 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu

BABY / Natus Medical, Inc. 8-K (Current Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 31, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jur

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year Ended December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Revenue $

Exhibit Natus Medical Announces Fourth Quarter and Full Year 2017 Financial Results ? Reports record fourth quarter revenue of $131.

Natus Medical Announces 2018 Annual and First Quarter Financial Guidance

Exhibit Natus Medical Announces 2018 Annual and First Quarter Financial Guidance ? Announces Fourth Quarter preliminary revenue results ? Announces Fourth Quarter 2017 Financial Results Conference Call Date Pleasanton, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a8-k2018annualguidance.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0

Employment Agreement between Natus Medical Inc. and Leslie McDonnell

EX-10.1 2 exhibit101lesliemcdonnell.htm EXHIBIT 10.1 Exhibit 10.1 NATUS MEDICAL INCORPORATED LESLIE MCDONNELL EMPLOYMENT AGREEMENT This Agreement is entered into as of January 3, 2018 (“Effective Date”), by and between Natus Medical Incorporated (“Company”), and Leslie McDonnell (“Executive”). 1.Duties and Scone of Employment. (a)Positions and Duties. As of the Effective Date, Executive will serve

Natus Appoints Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit

Exhibit Natus Appoints Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit PLEASANTON, Calif.

Financial Statements and Exhibits

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2018 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other juris

Current Report

Document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) Delaware 000-33001 77-0154833 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 baby9301710-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2017-q3earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 30, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year to Date September 30, 2017 September 30, 2016 September 30, 2017 September 30, 2016 Rev

Exhibit Natus Medical Announces Third Quarter 2017 Financial Results ? Reports record third quarter 2017 revenue of $122.

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

8-K 1 a2017-8xkintegralifescienc.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 6, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware

1

Exhibit Natus Completes Acquisition of Neurosurgery Assets from Integra LifeSciences PLEASANTON, CA (October 6, 2017) - Natus Medical Incorporated (NASDAQ: BABY) today announced that it has completed the acquisition of certain neurosurgery business assets from Integra LifeSciences that was announced on September 11, 2017.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 a2017-098xkincreasecredit.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 15, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delawar

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 f8k090917.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 11, 2017 Natus Medical Incorporated (Exact Name of Registrant as Specified in Charter) Delaware 000-33001 77-0154833 (State or Other Jurisdictio

Natus to Acquire Neurosurgery Assets from Integra LifeSciences, Enters Neurosurgery Market

EdgarFiling EXHIBIT 99.1 Natus to Acquire Neurosurgery Assets from Integra LifeSciences, Enters Neurosurgery Market Expands Natus product offering into neurosurgery market Expects acquisition to be immediately accretive to non-GAAP earnings Assets include Camino ICP monitoring product line and associated products PLEASANTON, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) - Natus Medical Incorporated (NAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-33001 NATUS

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 a2017-q2earnings8xk.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 30, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-015483

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited) (in thousands, except per share amounts) Quarter Ended Year to Date June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Revenue $ 122,227 $ 95,

Exhibit Natus Medical Announces Second Quarter 2017 Financial Results ? Reports record second quarter 2017 revenue of $122.

Current Report

8-K 1 a8-k2017submissionofmatter.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) Delaware 000-33001 77-0154833 (State or other jurisdiction o

Natus Medical 10-Q (Quarterly Report)

10-Q 1 baby3311710-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio

Natus Medical ADDITIONAL MATERIAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ( ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Definitive Proxy

Natus Medical DEFINITIVE PROXY STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14a Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ( ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Definitive Proxy

Financial Statements and Exhibits, Results of Operations and Financial Condition

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 31, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Delaware 77-0154833 (State or other jurisd

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (in thousands, except per share amounts) Quarter Ended March 31, 2017 March 31, 2016 Revenue $ 124,660 $ 87,329 Cost of revenue 56,913 32,469 Intangi

Exhibit Natus Medical Announces First Quarter 2017 Financial Results ? Reports first quarter 2017 revenue of $124.

Current Report

8-K 1 a20178-kdepartureofdirector.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) Delaware 000-33001 77-0154833 (State or othe

Combined financial statements for GN Otometrics A/S (Carve-out of the Otometrics business from GN Store Nord A/S) for the period January 1 2015 to December 31 2015 Otometrics A/S Hoerskaetten 9 DK-2630 Taastrup Denmark 1 Exhibit 99.1 COMBINED FINANCI

exhibit991gnotometrics20 Combined financial statements for GN Otometrics A/S (Carve-out of the Otometrics business from GN Store Nord A/S) for the period January 1 2015 to December 31 2015 Otometrics A/S Hoerskaetten 9 DK-2630 Taastrup Denmark 1 Exhibit 99.

Financial Statements and Exhibits

8-K/A 1 a20178-kagnotometricsacqui.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 3, 2017 Natus Medical Incorporated (Exact name of registrant as specified in its charter) 000-33001 (Commission File Number) Del